89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald
89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald
Canto Fitzgerald: Reiterated the 89bio (ETNB.US) rating and adjusted from an increase in holdings to an increase in holdings rating, with a target price of $29.00.
Canto Fitzgerald: Reiterated the 89bio (ETNB.US) rating and adjusted from an increase in holdings to an increase in holdings rating, with a target price of $29.00.
RBC Capital Remains a Hold on 89bio (ETNB)
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ionis Pharmaceuticals (IONS) and 89bio (ETNB)
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)
HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $29 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates 89bio with a Buy and maintains $29 price target.
Buy Rating for 89bio on Pegozafermin's Promise in Advanced NASH Trials
89bio Price Target Cut to $33.00/Share From $37.00 by Evercore ISI Group
89bio Price Target Cut to $33.00/Share From $37.00 by Evercore ISI Group
89bio Is Maintained at Outperform by Evercore ISI Group
89bio Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Group: Maintains 89bio (ETNB.US) rating, adjusted from better than market to better than market rating, and adjusted target price from $37.00 to $33.00.
Evercore ISI Group: Maintains 89bio (ETNB.US) rating, adjusted from better than market to better than market rating, and adjusted target price from $37.00 to $33.00.
Evercore ISI Group Maintains Outperform on 89bio, Lowers Price Target to $33
Evercore ISI Group analyst Liisa Bayko maintains 89bio (NASDAQ:ETNB) with a Outperform and lowers the price target from $37 to $33.
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial Of Pegozafermin In MASH Patients With Compensated Cirrhosis
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial Of Pegozafermin In MASH Patients With Compensated Cirrhosis
Oppenheimer Reaffirms Their Hold Rating on 89bio (ETNB)
It's worth revisiting! Wall Street mogul Cantor Fitzgerald: These 14 biotech stocks are undervalued
Cantor Fitzgerald, a well-known American financial services company, selected 14 biotech stocks in a recently released report and believes that these stocks are seriously undervalued and worth “re-examining.”
89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials
89bio Price Target Cut to $29.00/Share From $31.00 by HC Wainwright & Co.
89bio Price Target Cut to $29.00/Share From $31.00 by HC Wainwright & Co.
89bio Is Maintained at Buy by HC Wainwright & Co.
89bio Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on 89bio, Lowers Price Target to $29
HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and lowers the price target from $31 to $29.
Buy Rating Affirmed for 89bio Amid Promising Drug Candidate Progress and Strategic Readiness
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and comm
No Data